Key result
Targeting platelet-endothelial crosstalk may reduce pathological thrombosis while preserving hemostasis.
Why the study?
Targeting platelet-endothelial crosstalk has potential to reduce pathologic thrombosis while preserving hemostasis, but priorities remain in defining disease contexts, validating biomarkers, and conducting adequately powered trials.
Design
Review
Targeting the platelet-endothelial interface offers a promising strategy to reduce pathologic thrombosis without compromising hemostasis.
Targeting platelet-endothelial crosstalk has potential to reduce pathologic thrombosis while preserving hemostasis. Clinical proof of principle exists for focused approaches (anti-VWF in TTP; P-selectin blockade in vaso-occlusion; emerging GPVI inhibitors). Priorities are: defining disease contexts and timing where interface targeting is effective; validating biomarkers (VWF/ADAMTS13 ratio, soluble P-selectin, platelet activation signatures) for patient selection; and conducting adequately powered trials with rigorous bleeding endpoints.
No takes yet. Share an insight, caveat, or question.
Siobhan Branfield (2026) studied this question. Targeting platelet-endothelial crosstalk has potential to reduce pathological thrombosis while preserving hemostasis in various disease contexts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: